|
|
|
|
Stem-cell Transplantation Technique Reversed Sickle Cell Disease in Adults
Nonmyeloablative stem-cell transplantation reversed sickle cell disease in adults, according to a study in the New England Journal of Medicine.1 Myeloablative allogeneic hematopoietic stem-cell transplantation is curative in children with sickle cell disease;...
|
|
|
Arzerra, Fludara, and Cytoxan Promising for Previously Untreated CLL
The combination of Arzerra (ofatumumab), Fludara (fludarabine), and Cytoxan (cyclophosphamide) shows promising effectiveness in the initial treatment of chronic lymphocytic leukemia (CLL).These results were presented at the 2009 annual meeting of the...
|
|
|
Research and Markets: Pipeline Insight: Multiple Sclerosis - The Uptake of the First Oral Therapies to Result In the Market Value Peaking At $8.4 Billion in 2013
DUBLIN-- (BUSINESS WIRE) -- Research and Markets(http://www.researchandmarkets.com/research/145e0c/pipeline_insight) has announced the addition of the "" report to their offering.Sales of multiple sclerosis disease-modifying therapies exceeded $6.0 billion...
|
|
|
Research and Markets: Pipeline Insight: Multiple Sclerosis - The Uptake of the First Oral Therapies to Result
and has announced the addition of the '' report to their offering.Sales of multiple sclerosis disease-modifying therapies exceeded $6.0 billion in 2008 across the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK). Datamonitor...
|
|
|
Research and Markets: Pipeline Insight: Multiple Sclerosis - The Uptake of the First Oral
BusinessWire - Research and Markets(http://www.researchandmarkets.com/research/145e0c/pipeline_insight) has announced the addition of the 'Pipeline Insight: Multiple Sclerosis - Risk-benefit ratio under the spotlight for potent pipeline drugs' report to their...
|
|
|
Research and Markets: Pipeline Insight: Multiple Sclerosis - The Uptake of the First Oral Therapies
Research and Markets( www.researchandmarkets.com/research/145e0c/pipeline_insight : ) has announced the addition of the ' Pipeline Insight: Multiple Sclerosis - Risk-benefit ratio under the spotlight for potent pipeline drugs : ' report to their offering.
|
|
|
Research and Markets: Pipeline Insight: Multiple Sclerosis - The Uptake of the First Oral Therapies to Result In the Market Value Peaking At $8.4 Billion in 2013
GA_googleFillSlot("Press336"); GA_googleFillSlot("Press160"); DUBLIN - (Business Wire) Research and Markets(http://www.researchandmarkets.com/research/145e0c/pipeline_insight) has announced the addition of the "" report to their offering.Sales of multiple...
|
|
|
Research and Markets: Pipeline Insight: Multiple Sclerosis - The Uptake of the First Oral Therapies to Result
Research and Markets(http://www.researchandmarkets.com/research/145e0c/pipeline_insight) has announced the addition of the 'Pipeline Insight: Multiple Sclerosis - Risk-benefit ratio under the spotlight for potent pipeline drugs' report to their offering.
|
|
|
Research and Markets: Pipeline Insight: Multiple Sclerosis - The Uptake of the First Oral Therapies to Result In the Mar
ket Value Peaking At $8.4 Billion in 2013 DUBLIN - (BUSINESS WIRE) - Research and Markets(http://www.researchandmarkets.com/research/145e0c/pipeline_insight) has announced the addition of the "" report to their offering.Sales of multiple sclerosis disease...
|
|
|
Preventing infectious complications in patients with chronic lymphocytic leukemia
One of the most common supportive care challenges faced by the chronic lymphocytic leukemia patient is infectious complications.The increased risk for infectious complications compared with other malignancies arises from disease- and treatment-related...
|
|
|
Preventing infectious complications in patients with chronic lymphocytic leukemia
One of the most common supportive care challenges faced by the chronic lymphocytic leukemia patient is infectious complications.The increased risk for infectious complications compared with other malignancies arises from disease- and treatment-related...
|
|
|
EU committee issues positive opinion for GlaxoSmithKline, Genmab's Arzerra
GlaxoSmithKline and Genmab reported that the European Medicines Agencys Committee for Medicinal Products for Human Use issued a positive opinion recommending conditional approval of Arzerra (ofatumumab) for the treatment of refractory chronic lymphocytic...
|
|
|
GlaxoSmithKline, Genmab Get European Approval For Arzerra
LONDON -(Dow Jones)- The European Medicines Agency Thursday approved a new leukemia medicine from GlaxoSmithKline PLC (GSK.LN) and Denmark's Genmab A/S ( GEN.KO), although it still wants further data about the drug's long-term effects.The EMEA said it...
|
|
|
GlaxoSmithKline, Genmab Get European Approval For Arzerra (DJ)
Genmab Get European Approval For Arzerra Vendredi 22 jan 2010 12:48:35 L'offre EasyBourse Bourse sectoriels s de dirigeants d'experts de gestionnaires d'international d'association sur les actions sur les devises sur les taux Analyse Pdagogie Easybourse TV...
|
|
|
GlaxoSmithKline, Genmab Get European Approval For Arzerra
Dow Jones Newswires LONDON -(Dow Jones)- The European Medicines Agency Thursday approved a new leukemia medicine from GlaxoSmithKline PLC (GSK.LN) and Denmark's Genmab A/S (GEN.KO), although it still wants further data about the drug's long-term effects.The...
|
|
|
GlaxoSmithKline, Genmab Get European Approval For Arzerra
Dow Jones Newswires LONDON -(Dow Jones)- The European Medicines Agency Thursday approved a new leukemia medicine from GlaxoSmithKline PLC (GSK.LN) and Denmark's Genmab A/S (GEN.KO), although it still wants further data about the drug's long-term effects.The...
|
|
|
GlaxoSmithKline, Genmab Get European Approval For Arzerra
LONDON -(Dow Jones)- The European Medicines Agency Thursday approved a new leukemia medicine from GlaxoSmithKline PLC (GSK.LN) and Denmark's Genmab A/S ( GEN.KO), although it still wants further data about the drug's long-term effects.The EMEA said it...
|
|
|
Glaxo, Genmab win EU backing for leukaemia drug - Reuters
Tue, Jan 19 2010 Fri, Jan 8 2010 Sun, Jan 3 2010 * EMEA recommends Arzerra for chronic lymphocytic leukaemia Stocks| Regulatory News | Healthcare * Move follows U.S.FDA approval in October * Genmab shares up 5 pct, Glaxo flat (Updates with details on drug,...
|
|
|
UPDATE 1-Glaxo, Genmab win EU backing for leukaemia drug
* EMEA recommends Arzerra for chronic lymphocytic leukaemia * Move follows U.S.FDA approval in October * Genmab shares up 5 pct, Glaxo flat (Updates with details on drug, sales forecast, shares) LONDON, Jan 22 (Reuters) - GlaxoSmithKline (GSK.L: Quote,...
|
|
|
UPDATE 1-Glaxo, Genmab win EU backing for leukaemia drug
LONDON, Jan 22 (Reuters) - GlaxoSmithKline and Genmab won European backing for their leukaemia drug Arzerra on Friday, following a green light for the medicine from U.S.regulators in October. Arzerra is the first drug to reach the market from the labs of...
|
|
|
UPDATE 1-Glaxo, Genmab win EU backing for leukaemia drug
LONDON, Jan 22 (Reuters) - GlaxoSmithKline and Genmab won European backing for their leukaemia drug Arzerra on Friday, following a green light for the medicine from U.S.regulators in October. Arzerra is the first drug to reach the market from the labs of...
|
|
|
Alemtuzumab (CAMPATH-1H) for the Treatment of Acute Rejection in Kidney Transplant Recipients: Long-Term Follow-Up
Clatworthy MR et al.All rejection episodes responded to treatment with alemtuzumab but there was an excess of early infectionassociated death in this group. Longterm transplant survival was similar in both groups as was allograft function. Alemtuzumab (...
|
|
|
Genzyme Phase 3 Trial of Campath/Fludara Combination Shows Potential Benefit in Second-Line CLL
Oral Presentation of Interim Data Given at the American Society of Hematology Annual Meeting CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 7, 2009 - Genzyme Corporation (Nasdaq: GENZ) announced data from its CAM314 randomized Phase 3 clinical trial comparing ...
|
|
|
Genzyme Phase 3 Trial of Campath/Fludara Combination Shows Potential Benefit in Second-Line CLL
Genzyme Corporation (Nasdaq: GENZ) announced data from its CAM314 randomized Phase 3 clinical trial comparing Campath (alemtuzumab) in combination with Fludara (fludarabine phosphate) (FluCAM) to Fludara alone in patients with relapsed and refractory...
|
|
|
Genzyme Phase 3 Trial of Campath/Fludara Combination Shows Potential Benefit in Second-Line CLL
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ - News) announced data from its CAM314 randomized Phase 3 clinical trial comparing Campath (alemtuzumab) in combination with Fludara (fludarabine phosphate) (FluCAM) to Fludara alone in...
|
